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Abstract While studying on epigenetic regulatory mecha-
nisms (DNA methylation at C-5 of –CpG– cytosine and
demethylation of methylated DNA) of certain genes (FAS,
CLU, E-cadh, CD44, and Cav-1) associated with prostate
cancer development and its better management, we noticed
that the used in vivo dose of 5-aza-2′-deoxycytidine (5.0 to
10.0 nM, sufficient to inhibit DNA methyltransferase activity
in vitro) helped in the transcription of various genes with
known (steroid receptors, AR and ER; ER variants, CD44,
CDH1, BRCA1, TGFβR1, MMP3, MMP9, and UPA) and
unknown (DAZ and Y-chromosome specific) proteinsand the
respective cells remained healthy in culture. At a moderate
dose (20 to 200 nM) of the inhibitor, cells remain growth
arrested. Upon subsequent challenge with increased dose (0.5
to 5.0 μM) of the inhibitor, we observed that the cellular
morphology was changing and led to death of the cells with
progress of time. Analyses of DNA and anti-, pro-, and
apoptotic factors of the affected cells revealed that the
molecular events that went on are characteristics of
programmed cell death (apoptosis).
Keywords Epigenome.CpG hypermethylation.
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Abbreviations
DNMT(s) DNA methyltransferase(s)
HDAC(s) Histone deacetylase(s)
MBD(s) Methyl–CpG–DNA binding domain protein(s)
CaP Cancer of prostate
AzadC 5-Aza-2′-deoxycytidine
Introduction
Overexpression of DNA (cytosine-5-carbon) methyltrans-
ferases and hypermethylation of CpG islands at the
regulatory regions of certain genes (for example, ER,
CDH1, CD44, Casp3, GSTP1, MDR1, FAS, RASSF1A,
P15INK4B, and P16INK4A) and global genome-wide
hypomethylation are well known to be associated with
prostate and other multiple cancer development and
metastasis (Graff et al. 1995; Ferguson et al. 1997;L ie t
al. 2000; Szyf et al. 2000; Li et al. 2001; Nojima et al.
2001; Patra et al. 2001; Dasari et al. 2002; Jones and Baylin
2002; Patra et al. 2002; Sasaki et al. 2002; Chen et al. 2003;
Jaenisch and Bird 2003; Patra et al. 2003; Patra 2008a;
Patra et al. 2008a; Patra and Szyf 2008; Patra and Bettuzzi
2009). The CpG sites in these gene promoter regions are
rarely methylated in normal cells except in, e.g., inactivated
X-chromosome and imprinted genes. Some non-regulatory
site CpG island methylation has no direct effect on gene
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2008). It is now revealed that abnormal methylation of CpG
islands is not restricted to cancer cells but can also occur
during aging and during early stages of tumor development
(Patra et al. 2008a). While the co-existence of genome-wide
hypomethylation and site-selected hypermethylation are
well documented by chemical analyses of bases from total
genomic DNA and gene-specific DNA segment, the
specific mechanisms at the level of enzymes, co-
substrates, and repressor proteins are subject to immense
interest of current investigations (Ferguson et al. 1997;
Bhattacharya et al. 1999; Cervoni et al. 1999; Ramchandani
et al. 1999; Fuks et al. 2000; Ng et al. 2000; Peterson and
Logie 2000; Rhee et al. 2000; Szyf et al. 2000; Misteli
2001; Ohki et al. 2001; Patra et al. 2001; Cervoni et al.
2002; Di Croce et al. 2002; Jones and Baylin 2002; Patra et
al. 2002, 2003; Pogribny and James 2002; Jaenisch and
Bird 2003; Patra 2008a; Patra et al. 2008a; Patra and Szyf
2008; Patra and Bettuzzi 2009).
5-Aza-2′-deoxycytidine (AzadC), when incorporated
into the genomic DNA in sites to be occupied by cytosine
during replication, is best known as an inhibitor of DNA
methyltransferases (DNMTs—DNMT1, DNMT3A, and
DNMT3B) through covalent adduct formation with the
enzyme (Patra and Bettuzzi 2009). Since the methylation
target for the mammalian maintenance methyltransferase,
DNMT1, is CpG in hemi-methylated sites, significant
inhibition of DNA synthesis, even due to complete lack
of repair of DNMT1–AzadC adducts, does not occur for at
least two cell cycles. In contrast, DNMT1 becomes bound
to DNA and inactivated as soon as AzadC is incorporated
into CpG sites opposite to methylated CpG sites on the
template strand, i.e., within a few hours of initiating
treatment with AzadC. This in turn leads to rapid passive
loss of methylation. There is plenty of evidence that
treatment of cancers with AzadC leads to reactivation of
function in tumor cell lines in which one copy of a gene for
a tumor suppressor, a cell cycle regulator, or a DNA repair
enzyme is muted and the complementary is normal (wild
type) but inactivated by methylation (Graff et al. 1995;L ie t
al. 2000; Wijermans et al. 2000; Li et al. 2001; Nojima et
al. 2001; Christman 2002; Patra et al. 2002; Chen et al.
2003; Claus et al. 2005; Yoo and Jones 2006). This
suggests that loss of methylation induced by AzadC
treatment can lead to reactivation of the same gene whose
inactivation was programmed/selected during development
of a specific tumor and has stimulated interest in revisiting
the use of AzadC and analogs in therapeutic intervention of
cancer (Wijermans et al. 2000; Christman 2002; DeSimone
2004; Claus et al. 2005; Lavelle et al. 2006; Yoo and Jones
2006; Lavelle et al. 2008; Patra and Bettuzzi 2009). But
along with expression of desired curative genes (for
example, ER, AR, and CDH1), some unwanted genes that
code proteins enhancing metastasis (lipid raft associated
genes, UPA and MMPs) could be expressed even at a low
non-toxic dose of the drugs, thus creating complications in
the use of this chemotherapeutic agent (Sato et al. 2003;
DeSimone 2004; Lavelle et al. 2006; Hellebrekers et al.
2007; Patra and Bettuzzi 2009). Since the 1970s, there have
been many studies on the toxicity of AzadC. The early
studies were mostly devoted to understanding various toxic
effects on the basis of physiology and genetics (Christman
2002). The present study was designed to investigate the
systematic molecular and epigenetic effects of 5-azadC on
the DNMTactivity and expression, and on cell growth. The
data presented in this work provide strong evidence that
the cells died by epigenetic stress-induced apoptosis
when challenged with higher dose (∼5.0 μM, which is
far above the DNMT inhibitory concentration) of the
drug 5-azadC. The results show that Bcl2 and DNMT1
genes are not repressed; rather, they overexpressed dose
dependently of 5-azadC when supplemented with the cell
culture media. DNMT1 enzyme activity was reduced,
perhaps due to adduct formation with DNA containing
5-azadC replacing cytosine. Gradual increase of 5-azadC
in cell culture medium caused dose-dependent over-
expression of apoptosis genes like Bak, Bax, and
caspase-3, including many other genes in TSUPr1 and
DuPro cell lines (Table 3).
Experimental procedures
Cell culture and drug(s) treatment
Prostatic cancer cell lines of human origin PC3, TSUPr1,
and DuPro were purchased from American Type Culture
Collection (Manassas, VA, USA). Cell lines were
cultured and maintained in RPMI 1640 supplemented
with 10% (v/v) fetal bovine serum, 2 mML-glutamate,
and 0.1 μM of penicillin and streptomycin. Media and
supplements were obtained from the University of
California at San Francisco Cell Culture Facility. For drug
treatment, exponentially growing cells were seeded at a
density of ∼10
6 cells/75 cm
2 flask. After 6 h, the cells
were treated at different concentrations (nanomolar to
micromolar) of 5-azadC (Sigma Chemical Co., St. Louis,
MO, USA) and marked as zero “0” time. Trichostatinn A
was dissolved in PBS and diluted with the required
volume of the medium, and cells were also treated at
different concentrations (4, 10, and 50 nM) of MG-132
(Calbiochem, San Diego, CA, USA) inhibitor of protea-
some, dissolved in DMSO and diluted with the required
volume of medium for 8–12 h prior to harvest for further
investigations. All cells were harvested after 96 h unless
otherwise mentioned.
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The DNMT enzymatic activity was measured following a
previous protocol as standardized in our laboratory (Patra et
al. 2001, 2002, 2003). Poly•dI–dC duplex or poly•dG–dC
duplex was used as substrate and S-adenosylmethionine
(tritiated methyl) as methyl group donor. All assays were
performed in duplicates in three sets of independent
experiments. Background levels were determined in assays
in which the template DNA was omitted. Statistical
analyses were performed using Student’s t test.
Caspase-3-like activity was measured according to the kit
supplied by Calbiochem. Caspase-3 assay kit employs the
colorimetric substrate DEVD-pNA that upon cleavage exhib-
its increased absorption at 405 nm. A caspase-3 inhibitor
(Ac-DEVD-CHO) is also used as a prototypic control
inhibitor. The DEVD amino acid sequence is derived from
the caspase-3 cleavage site in PARP. All the kit components
were thawed and immersed in an ice bath until use. Briefly,
caspase-3 inhibitor I was warmed to room temperature. In a
separate microcentrifuge tube, it was diluted in assay buffer
(1:200). Caspase-3 (15 μl, approximately 30 U) diluted in
assay buffer (1:50) was used as control. Caspase-3 was not
usedinassaybuffertoblanks.Caspase-3inhibitor (20μl)was
added in triplicate tubes. Reaction was started by adding
200 μM (final concentration) caspase-3 substrate I and pre-
equilibrated to assay temperature at 25°C and measured in a
colorimeter/microplate reader.
Histone deacetylase (HDAC) enzymatic activity was
measured using fluorescent amide, N-(4-methyl-7-coumar-
inyl)-N-α-(tert-butyloxy-carbonyl)-N-Ω-acetyllysinamide
(MAL) (Calbiochem) as a potential substrate following the
published protocol of ours and other laboratories (Patra et
al. 2001; Cervoni et al. 2002) as well as using a radioactive
kit (Upstate Biotechnology). The background fluorescence
was kept significantly low using filters, and nanomolar
(nM) concentration of MAL was used to avoid interference
(inner-filter effects). In the presence of trichostatin A
(Calbiochem), a potent inhibitor of HDAC (Taunton et al.
1996; Hoffmann et al. 1999), no activity was observed (see
also Patra et al. 2001, 2003). Statistical analyses were
performed using Student’s t test.
Nucleic acid extraction and reverse transcription–PCR
Total RNA was extracted using TRI Reagent (Molecular
Research Center, Inc., Cincinnati, OH, USA). Cytosolic and
nuclear RNA were prepared using TRI reagent after control
lysing of cells and separation by centrifugations of those
contents. RNA (1–2 μg) was reverse transcribed using
random hexamer primers and Superscript II, reverse
transcriptase (Life Technologies Inc., Gaithersburg, MD,
USA) in a 25-μl reaction volume. cDNA was amplified by
PCR using primers specific for the genes Bcl2, Bak, Bax,
Bcl-XL, and caspase-3. β-Actin, glyceraldehyde-3-
phosphatedehydrogenase (GAPDH), and histone 4 (H4)
genes were also amplified as internal controls to ensure
high quality. Primer sequences specific for β-actin
gene (TCTACAATGAGCTGCGTGTG, sense;
ATCTCCTTCTGCATCCTGTC, antisense), GAPDH gene
(GAAGGTGAAGGTCGGAGTC, sense; GAAGA
TGGTGATGGGATTTC, antisense), and H4 gene (CAA
CATTCAGGGCATCACCAA, sense; CCCGAATCA
CATTCTCCAAGAA, antisense) were used and resulted
in 682-, 226-, and 131-bp products, respectively. The PCR
sample mixtures, in a 10-μl volume, contained 1× PCR buffer
(Sigma), 0.2 mM of each dNTP (Sigma), 4 ng of TaqStart
antibody (Clonetech, Palo Alto, CA, USA), 0.2 μMp r i m e r s ,
and 0.5 μl RedTaq DNA polymerase (Sigma). PCR reactions
were performed in a PTC-200 thermal cycler (MJ Research,
W a t e r t o w n ,M A ,U S A )a t9 4 ° Cf o r1m i n ,2 6c y c l e sa t9 4 ° C
for 20 s, 57°C for 20 s, and 72°C for 30 s, followed by an
extension step at 72°C for 5 min. The PCR products were
electrophoresed through a 1.2% agarose gel containing
ethidium bromide and were visualized by UV detection.
Immunocytochemistry
Prostatic cancer cell lines were grown in chamber slides
and stained as our standardized protocol (Patra et al. 2001,
2002, 2003). In brief, sub-confluent cells were fixed by
10% formalin and were permeabilized by 0.1% triton
X-100 in PBS. The endogenous peroxidase activity was
blocked by incubation in 5% H2O2 in methanol for 20 min.
The cells were pre-blocked using Ultra V block (Lab
Table 1 Comparison of % activity (average of three sets of independent experiments) of the enzymes without and with increasing concentration
of drug
Enzymes Control 5-AzadC (nM)
10 20 35 50 75 100 250 500
DNMT 100 71.23 50.36 5.14 2.32 –– – –
HDAC 100 90.62 81.07 nd 73.34 61.58 nd nd nd
Caspase-3 – ––– –2.3±1.73 5.67±3.46 27.5±8.40 41.49±7.0
nd not detected
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incubated for overnight at 4°C with goat polyclonal
antibody against caspase-3 (Santa Cruz Biotech, CA,
USA) New Zealand white rabbits polyclonal antibody
against DNMT1 peptide (I0015801K; Research Genetics,
Inc., Huntsville, AL, USA; or met-cat 2) and goat
polyclonal antibody against Bcl2, Bak, Bax, BclXs, and
MBD1 (Santa Cruz Biotech). The antibody for HDAC1
(1:100), DNMT1 (1:1,000), and others was diluted
according to the manufacturer’s instructions (and several
titration) with primary antibody dilution buffer (Bio-
meda, Foster City, CA, USA). The cells were washed in
PBS then incubated with anti-goat biotinylated secondary
antibody (Santa Cruz Biotech) for 30 min followed by
another wash and incubation with HRP-conjugated
streptavidin. Finally, reactions were visualized by incu-
bation with DAB (substrate and chromogen) and counter-
staining with Harris hematoxylin. For negative control,
cells were incubated overnight with dilution buffer (no
primary antibody).
TUNEL assays
Cells were permeablized with 0.1% Triton for 2 min, fixed
for 10 min in 4% paraformaldehyde in PBS, and stored in
70% ethanol before assay. Slides were equilibrated in
terminal transferase (Roche) and incubated for 60 min with
TdT (200 U/ml) and biotin-16-dUTP (10 μM; Roche).
Following two washes with 4× SSC, TUNEL-positive cells
were detected with avidin–Texas Red (1:100; Jackson).
Results
In vitro DNMTase, HDACs, and caspase-3 activity:
inhibition of DNMT activity is not sufficient for induction
of caspase-3 activity
The measurement of DNMTase enzyme activity, using poly
(dI–dC) and poly (dG–dC) duplex as substrates, in cancer
cell lines (PC3, TSUPr1, and DUPro) and tissues (post-
Fig. 1 Hematoxylin and eosin
(H&E) staining of TSUPr1 cells
showing apoptotic damage to
the drug treated cells (a without
5-azadC; b with 5.0 μM5 -
azadC) and immunocytochemis-
try of TSUPr1 cells directed
against caspase-3 antibodies.
Sub-confluent cells were fixed
by 10% formalin and were per-
meabilized by 0.1% triton X-
100 in PBS. The endogenous
peroxidase activity was blocked
by incubation in 5% H2O2 in
methanol for 20 min. The cells
were pre-blocked using Ultra V
block (Lab Vision) for 10 min
and incubated overnight at 4°C
with goat polyclonal antibody
against caspase-3. No expres-
sion of caspase-3, control (c);
expression of caspase-3 in
0.5 μM 5-azadC-treated cells (d)
342 Clin Epigenet (2011) 2:339–348operated tissues obtained from UCSF and VA Medical
Center, San Francisco) showed the increased activity in
cancer, and it is clear that in prostate cancer expression of
DNMT is very high as compared to BPH-1 cell line and
BPH tissues. Enzyme activity of HDAC in prostate cancer
is also higher than normal or BPH (Patra et al. 2001, 2003).
There was no expression of caspase-3 activity in prostate
cancer cell lines. Treatment of cells with 10, 20, 35, 50, 75,
100, 250, and 500 nM 5-azadC respectively supplemented
in culture medium abolished the in vitro DNMT activity
Control 250nM 5-azadC treatment
Control 250nM 5-azadC treatment
Control 250nM 5-azadC treatment
ab
cd
ef
Fig. 2 Immunocytochemistry.
Sub-confluent cells were fixed
by 10% formalin and were per-
meabilized by 0.1% triton X-
100 in PBS. The endogenous
peroxidase activity was blocked
by incubation in 5% H2O2 in
methanol for 20 min. The cells
were pre-blocked using Ultra V
block (Lab Vision) for 10 min
and incubated for overnight at
4°C with respective antibodies.
The cells were washed in PBS
then incubated with anti-goat
biotinylated secondary antibody
(Santa Cruz Biotech) for 30 min
followed by another wash and
incubation with HRP-
conjugated streptavidin. Finally,
reactions were visualized by
incubation with DAB (substrate
and chromogen) and counter-
staining with Harris hematoxy-
lin. For negative control, cells
were incubated overnight with
dilution buffer (no primary anti-
body). Representative examples
of expression of Bcl2 in un-
treated TSUPr1 (a). In 250 nM
5-azadC-treated TSUPr1 cells,
the amount of expression of
Bcl2 was very high (b).
Caspase-3: there was no expres-
sion in control/untreated
TSUPr1 (c). The amount of
expression in 5-azadC 250 nM
5-azadC-treated TSUPr1 cells
was very high (d). Bax: there
was no expression in control/
untreated TSUPr1 (e), reason-
able in 5-azadC 250 nM 5-
azadC-treated TSUPr1 cells (f)
Clin Epigenet (2011) 2:339–348 343around 75 nM and significantly decreased HDAC activity
in BPH-1, DuPro, and other cancer cell lines. Although in
the TSUPr1 cells the DNMT enzyme activity was blocked
at 50/75 nM of 5-azadC, the significant caspase-3 activity
was traced around 250 nM (see Table 1 for details).
Effect of drugs (5-azadC, DEVD-CHO, and MG-132)
on cell growth
The hypomethylating agent 5-azadC is known to block
DNMTs activity by forming covalent adducts with the
daughter strand in replicating cells/organisms (Patra and
Bettuzzi 2009). We found that in culture medium supple-
mented with 5-azadC at concentrations of 10, 20, 35, 50,
75, and 100 nM, the cells grow well. A gradual decrease in
growth rate (i.e., increase in cell doubling time) was
observed in all cases beyond 75 nM. All prostate cancer
cell lines showed a significantly similar pattern of decrease
in enzyme activity and growth rate, except PC3 cell line.
The cancer cell line PC3 was found to be highly prone to
death at low, 35-nM concentrations of 5-azadC compared to
other cancer cell lines (for example, TSUPr1 and DuPro)
that needed the drug concentration at 350 to 500 nM range
(about 100 times higher) for growth arrest and very high
concentrations (1.0–5.0 μM) of drug to undergo death. We
found that the use of 50-nM concentration of 5-azadC in the
culture medium of growing cells (thus incorporated into the
genomic DNA) completely inactivated the enzyme DNMT
activity to methylate either of the substrates poly(dI–dC)
and poly(dG–dC) in vitro, but the cells grew well. At higher
dose around 250 nM, cells were growth arrested and
changes in morphology were observed. The morphology
of the cells (Fig. 1a, b and inset) around 250 nM to 5 μM
indicates that this change is due to apoptosis induced by the
drug. At lower dose (below 50 nM) of MG-132 (protea-
some inhibitor) and DEVD-CHO (caspase-3 inhibitor), no
effective cell growth retardation or arrest and no change in
morphology have been observed.
Inactivation of DNMT1 causes DNA hypomethylation and
activation of caspase-3, Bak, Bax, and Bcl-XL and over-
expression of Bcl2 and DNMT1
The expression of Bak, Bax, Bcl-XL, caspase-3, DNMT1,
and HDAC1 as visualized by immunocytochemistry meth-
od is represented in Fig. 2a–f and summarized in Table 2.I t
is clear that the expression of pro-apoptotic factors and
caspase-3 was triggered by higher doses of the 5-azadC and
Fig. 4 Caspase-3 activity of purified enzyme, and 100, 250, 500 nM,
and 5.0 μM 5-azadC-treated TSUPr1 cells lysates, and of 250 nM 5-
azadC-treated TSUPr1 cell lysates in presence of caspase-3 inhibitor
(Ac-DEVD-CHO). Among different TSUPr1 cell lysates, activity is
maximum at 500-nM concentration of 5-azadC. A control (without
drug treatment) TSUPr1 cell lysate had no caspase-3 activity and not
shown in the figure
Fig. 3 RT–PCR: expression of mRNA of Bak, Bax, Bcl2, and
caspase-3 at various concentration of 5-azadC. β-Actin gene was used
as positive control for this experiment (see “Experimental procedures”
for further details)
Proteins Cells
Control (no drug treatment) 5-Aza-2′-deoxycytidine (250 nM)
PC-3 TSUPr1 DuPro PC3 TSUPr1 DuPro
Caspase-3 −− − na +++ +++
Bcl2 nd ++ ++ na +++ +++
Bak nd −− na ++ ++
Bax nd −− na + +
Bcl-XS nd −− na ++ ++
DNMT1 ++ ++ ++ na +++ +++
HDAC1 ++ ++ ++ na + +
Table 2 Immunocytochemistry
results
+++High,
++medium, and
+low
expression, − no expression, nd
not detected, na not applicable;
PC3 cells died at very low dose
(35 nM)
344 Clin Epigenet (2011) 2:339–348the anti-apoptotic factor Bcl2, and DNMT1 expressions
were increased significantly. This is understandable and can
be explained in the way that, as DNA methylation is a post-
replicative process and DNMT1 is trapped by DNA at N-5
of 5-azadC, cells produce more and more DNMT1. On the
other hand, Bcl2 overexpression can be explained in the
way that anti-apoptotic factor is fighting to keep the cell to
strive under the threat imposed by higher concentration of
the drug. mRNA expression of DNMT1 and Bcl2 was not
decreased due to 5-azadC treatment up to 500 nM. We also
tested the HDAC activity of the 50-nM-drug-treated cell
lines and found a 15–20% decrease in cancer cell lines. The
decrease in HDAC1 mRNA expression in cancer cell lines
by 50 nM 5-azadC was confirmed by RT–PCR analyses.
The 5-azadC dose-dependent expression of Bak, Bax,
Bcl-XL, and caspase-3 mRNA in prostate cancer cell line
TSUPr1 is represented in Fig. 3. DuPro cell line also
showed similar pattern. The proteasome inhibitor MG-132
at considerably higher concentration (>250 nM) induced
cell death by blocking the ubiquitin–proteasome pathway
and thus by the accumulation of unwanted protein
components with the cytosol which eventually disturbs
intracellular trafficking. We found that at reasonably lower
concentration up to 50 nM of MG-132, the cell growth was
not arrested.
Caspase-3 activity
Caspase-3 was induced in PC3, TSUPr1, and DuPro cell
lines using 250 nM 5-azadC in culture medium. For drug
treatment, exponentially growing cells were seeded at a
density of ∼10
6 cells/75 cm
2 flask. After 6 h, the cells were
treated at different concentrations (nanomolar to micromo-
lar) of 5-azadC and cells were collected for biochemical
investigation when they were 90% confluent. Induction of
caspase-3 gene and expression of the protein are visualized
by RT–PCR and immunochemistry, respectively. However,
it did not confirm that caspase-3 was functionally active. To
confirm that caspase-3 was active, we measured the enzyme
activity of the cellular extracts of cultured TSUPr1 cells at
different concentrations of 5-azadC (Fig. 4 and Table 1).
DEVD-pNAwas used as the substrate and purified caspase-
3 (Calbiochem) used as reference/positive control. It is
apparent that even complete inhibition of DNMTase
activity using AzadC in between 50 and 75 nM in culture
(as reflected by in vitro measurement of DNMTase activity)
does not result in caspase-3 activity (Table 1). Higher dose
(>75 nM) of the drug is necessary for significant expression
and activity of caspase-3, and we observed that at 250 nM
concentration of 5-azadC the caspase-3 activity is optimum
for characterizing apoptotic factors and reaches a maximum
around 500 nM of 5-azadC. Use of DEVD-CHO as
inhibitor of caspase-3, simultaneously with 5-azadC,
prevented the cell death and in vitro caspase activity
partially. Hence, our result supports that death was due to
caspase-3 activation. TUNEL assay also confirmed that the
cells died due to apoptosis (figure not shown).
Discussion
Overexpression of active DNA methyltransferase and
deregulation of cell proliferation in conjunction with the
suppression of apoptosis constitutes a minimal common
platform for the initiation and progression of most
neoplastic lesions. Cells of the normal adult prostate or
those constituting primary prostate cancer are dependent on
androgen/estrogen for survival and proliferation. Upon
withdrawal of androgen, the rate of apoptosis overtakes
the rate of cell proliferation, thereby causing involution of
the normal prostate and regression of the tumor. On the
other hand, estrogen has a palliative effect on prostate
cancer. The essential role for aberrant DNA methylation,
especially repression of androgen, estrogen, and progester-
one, and many Y-chromosome specific genes associated
with CpG-island promoter hypermethylation in the devel-
opment of prostate cancer, and E-cadherin and CD44
inactivation associated with metastasis, led us to address
the requirement for demethylation/hypomethylation in-
duced re-expression and reversal of prostate cancer (Li et
al. 2000, 2001; Wijermans et al. 2000; Nojima et al. 2001;
Patra et al. 2001, 2002, 2003, 2008a; Dasari et al. 2002;
Sasaki et al. 2002; Sato et al. 2003; DeSimone 2004;
Lavelle et al. 2006; Yoo and Jones 2006; Hellebrekers et al.
2007; Lavelle et al. 2008; Table 3). In view of this, we had
revisited the effects of 5-azadC as potential therapeutic
agent for the treatment of prostate cancer. Our results
clearly indicate that the enhanced expression of DNA
methyltransferase and hyperactivity of the enzyme is
associated with the disease prostate cancer (Patra et al.
Table 3 Re-expressed genes in prostate cancer cells by application of
5-azadC in culture
Low-dose (<10 nM) genes High-dose (>20 to 500 nM) genes
Steroid receptors (SR—AR
and ER)
Bak
ER variants Bax
CD44 Bcl-Xs
CDH1 Caspase-3
BRCA1 MDR1
TGFβR1
UPA
DAZ
Y-chromosome specific
Clin Epigenet (2011) 2:339–348 3452001, 2002, 2003). 5-AzadC cannot prevent expression of
DNMT (Patra and Bettuzzi 2009) or anti-apoptotic factor
Bcl2 but helps in the expression of various steroid receptors
like AR, ER, PR and E-cadherin, CD44 tumor suppressor,
and cell cycle regulatory and various Y-chromosome-
specific genes with unknown protein function (Table 3).
The re-expression can lead to remission of the cancer. A
higher dose of the drug can induce the expression of
apoptotic factors and hence can be used for retardation of
tumor growth. Apoptosis is characterized by stereotypic
morphological changes like chromatin condensation, cyto-
plasmic shrinkage, lipid like phosphatidylserine (PS)
exposure on cell membrane, membrane rupture and
segregation of lipid raft-associated cell surface marker
proteins, zeiosis, and formation of apoptotic bodies (Ferguson
et al. 1997; Gurumurthy et al. 2001; Jackson-Grusby et al.
2001; Patra and Patra 2003). The biochemical and molecular
pathways involved in apoptosis can be approximately
grouped as “private” pathways and “common” pathways.
The “private” pathways induced by diverse insults converge
on a “common” pathway comprising of a set of molecular
components collectively known as caspases that activate a
cascade of proteolytic events compelling to DNA fragmen-
tation. Among the various insults by chemical agents and
UV radiation, induced damage or FasL–FADD induced
activation of pro-caspase-8 or p53→Bax→cytochrome c
induced activation of Apaf-1/caspase 9 ultimately leads to
activation of caspase 3 and leads to death (apoptosis)
(Gurumurthy et al. 2001; Patra 2008b). We have demon-
strated that treatment of prostate cancer cell lines with 5-
azadC overexpressed Bcl2 and DNMT1 in prostate cancer
cell lines TSUPr1, DuPro, and PC3 dose dependently. The
Bcl-2 gene has been implicated in a number of cancers,
including melanoma, breast, prostate, and lung carcinomas,
as well as schizophrenia and autoimmunity. It is also thought
to be involved in resistance to conventional cancer treatment.
This supports a role for Bcl2 in decreased apoptosis in the
pathogenesis of cancer, including prostate cancer. DNMT1
overexpression in prostate and other cancers have been
implicated to repress various cell cycle regulatory genes by
promoter methylation and inactivation of genes. However,
these two proteins could not prevent apoptosis of the
respective cells (TSUPr1, DuPro, and PC3) at higher
concentrations of the drug. The morphology of the 5-
azadC-treated TSUPr1 and other cells is characteristic for
apoptotic cells, a biochemical process initiated by expression
of Bak and Bax and finally completely destructed by
activated caspase-3 activity. 5-Aza-2′-deoxycytidine, an ana-
log of cytosine base (Wijermans et al. 2000; Christman 2002;
Sato et al. 2003;D e S i m o n e2004; Claus et al. 2005; Lavelle
et al. 2006; Yoo and Jones 2006; Hellebrekers et al. 2007;
Lavelle et al. 2008; Patra and Bettuzzi 2009), has the
potential to kill tumor cells. The genotoxic stress imposed to
the surrounding normal cells and epigenetic reprogramming
due to inclusion of 5-azadC in the genome of the cells has
bedeviled and questioned its therapeutic use (Ferguson et al.
1997;N ge ta l .2000; Kress et al. 2001;L ie ta l .2004;
Pakneshan et al. 2004; Jones and Baylin 2007; Patra and
Bettuzzi 2007; Zhu and Yao 2007; Patra et al. 2010). Potent
inhibitors of DNA methylation with less side effects and
toxicity originating from bioflavonoids, including tea
catechins and other death-inducing membrane raft
orchestrating drugs, are emerging (Fang et al. 2003;
Miyaji et al. 2005; Mollinedo and Gajate 2006; Patra and
Bettuzzi 2007;P a t r a2008b; Patra et al. 2008b; Patra and
Szyf 2008).
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